Table 2.
Synthesis of major findings from case reports on COVID-19-triggered Hashimoto’s thyroiditis (HT).
| STY | YR | CTR | Sex | Age | CVDS | TCD | HOSP | Prev. TD | TFT | MYP | CK | TX | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| This study | 2023 | Singapore | M | 33 | Moderate | 14 | Yes | No | TSH: 216 mIU/L, T4: <5.50 pmol/L, TPO: 78.53 IU/mL | Yes | 5358 IU/L | Levothyroxine | The patient responded well to the treatment |
| Khaja, Qureshi et al 2022[9] | 2022 | USA | F | 34 | Asymptomatic | 0 | No | No | TSH: 47.10 mIU/L, T3: 34 ng/dL, T4: 0.15 μg/dL | No | 1154 IU/L | Levothyroxine | The patient responded well to the treatment |
| Das, Ali et al 2022[6] | 2022 | India | M | 33 | Severe | 14 | Yes | NR | TPO: 159 IU/mL | No | NR | Deflazacort 5 mg + psychiatric medication | The patient responded well to the treatment |
| Tee, Harjanto et al 2021[7] | 2021 | Singapore | M | 45 | Mild | 7 | No | No | TSH: 6.49 IU/mL, T4: 9.19 pmol/L, TPO levels > 2000 IU/mL | No | Normal | Levothyroxine | The patient responded well to the treatment |
| Knack, Hanada et al 2021[36] | 2021 | Brazil | F | 33 | NR | 20 | No | No | TSH: 8 mIU/mL, free T4: 0.5 ng/dL, anti-TPO: 115 IU/mL | No | NR | Levothyroxine | Euthyroidism was achieved 4 months later |
| Feghali, Atallah et al 2021[37] | 2021 | USA | F | 38 | Mild | 42 | No | No | TSH: 136 mIU/L, free T4: 0.2 ng/dL, anti-TPO > 900 IU/mL, anti-thyroglobulin antibodies > 1000 IU/mL | No | NR | Levothyroxine | Euthyroidism was achieved 1 month later |
| Allam, El-Zawawy et al 2021[38] | 2021 | Egypt | F | 42 | Mild | 8 | No | HT for 10 years | TSH: 2.1 mIU/mL, FT4: 1.46 ng/dL, FT3: 3.46 pg/mL | No | NR | Levothyroxine | Euthyroidism was achieved 2 months later |
| Dixit, Truong et al 2020[8] | 2020 | USA | F | 69 | NR | 0 | Yes | NR | TSH: 61.3 μU/mL, fT4: 0.2 ng/dL, TPO: 33.4 | No | 1908 IU/L | N |
Anti-TPO = Antithyroid peroxidase, CK Lvls = Creatine Kinase (CK) Levels, CTR = Country, CVDS = COVID-19 Severity, Free T4 = Free thyroxine, GDR = Gender/ Sex, HOSP = Hospitalization for COVID-19, HT = Hashimoto’s thyroiditis, MYP = Myopathy, NR = Not reported, Outcome = Study Outcome/ Research Findings, Prev. TD = Previous Thyroid Disease, STY = Study, TCD = Time Since COVID-19 Diagnosis, TFT = Thyroid Function Test, TSH = Thyroid-stimulating hormone, TX = Treatment/Intervention, YR = Study Year/ Data Collection Year.